World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
49
Citations
8391
World Ranking
4352
National Ranking
183

Overview

Carlo Antozzi is affiliated with the Fondazione IRCCS Istituto Nazionale dei Tumori in Italy, where their research primarily focuses on neurology and related medical disciplines. Their scholarly output spans a range of topics within medicine, emphasizing neurological disorders and immunology.

The main fields of study in which Antozzi works include:

  • Medicine

Within this broad domain, their research delves deeply into several subfields:

  • Neurology
  • Infectious Diseases
  • Oncology
  • Pathology and Forensic Medicine
  • Radiology, Nuclear Medicine and Imaging

Antozzi's core topical research concentration covers:

  • Myasthenia Gravis and Thymoma
  • Peripheral Neuropathies and Disorders
  • Parkinson's Disease and Spinal Disorders
  • Antifungal resistance and susceptibility
  • Multiple Sclerosis Research Studies
  • Cancer Treatment and Pharmacology
  • SARS-CoV-2 and COVID-19 Research

Their publication record features several notable papers, including:

  • Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis, 2023, published in Neurology
  • Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial, 2021, published in The Lancet Neurology

Though Antozzi is a coauthor on important works in the field, some key recent publications on related topics include studies led by other scholars such as James F. Howard and Maria Pia Sormani, covering myasthenia gravis and COVID-19 impacts in neurological contexts.

Frequent collaborators of Carlo Antozzi include:

  • Renato Mantegazza
  • Rita Frangiamore
  • Fiammetta Vanoli
  • Vera Bril
  • Silvia Bonanno

The primary venues for Antozzi's publications are:

  • Neurology
  • Neurological Sciences
  • Neuromuscular Disorders
  • Zenodo (CERN European Organization for Nuclear Research)
  • The Lancet Neurology

Best Publications

  • Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

    James F Howard;Kimiaki Utsugisawa;Michael Benatar;Hiroyuki Murai

  • A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis

    P. Zisimopoulou;P. Evangelakou;J. Tzartos;K. Lazaridis

  • Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures.

    Renato Mantegazza;Pia Bernasconi;Fulvio Baggi;Roberto Spreafico

  • Experience with immunomodulatory treatments in Rasmussen’s encephalitis

    Tiziana Granata;L. Fusco;G. Gobbi;E. Freri

  • Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus

    Paola Cavalcante;Barbara Serafini;Barbara Rosicarelli;Lorenzo Maggi

  • A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy

    R. Mantegazza;E. Beghi;E. Beghi;D. Pareyson;C. Antozzi

  • Long-term selective IgG immunoadsorption improves Rasmussen's encephalitis

    Carlo Antozzi;T. Granata;N. Aurisano;G. Zardini

  • Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience

    Lorenzo Maggi;Francesca Andreetta;Carlo Antozzi;Fulvio Baggi

  • Breakdown of Tolerance to a Self-Peptide of Acetylcholine Receptor α-Subunit Induces Experimental Myasthenia Gravis in Rats

    Fulvio Baggi;Andrea Annoni;Federica Ubiali;Monica Milani

  • Current and emerging therapies for the treatment of myasthenia gravis

    Renato Mantegazza;Silvia Bonanno;Giorgia Camera;Carlo Antozzi

  • The thymus in myasthenia gravis: Site of "innate autoimmunity"?

    Paola Cavalcante;Rozen Le Panse;Sonia Berrih-aknin;Lorenzo Maggi

  • Complete stable remission and autoantibody specificity in myasthenia gravis.

    Fulvio Baggi;Francesca Andreetta;Lorenzo Maggi;Paolo Confalonieri

  • MuSK autoantibodies in myasthenia gravis detected by cell based assay — A multinational study

    A.I. Tsonis;A.I. Tsonis;P. Zisimopoulou;K. Lazaridis;J. Tzartos

  • A short plasma exchange protocol is effective in severe myasthenia gravis.

    Carlo Antozzi;Marco Gemma;Bruno Regi;Emilia Berta

  • Antigen-specific modulation of experimental myasthenia gravis: Nasal tolerization with recombinant fragments of the human acetylcholine receptor α-subunit

    Dora Barchan;Miriam C. Souroujon;Sin-Hyeog Im;Carlo Antozzi

  • Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis.

    P. Cavalcante;M. Barberis;M. Cannone;F. Baggi

  • Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.

    Renato Mantegazza;Piercarlo Cristaldini;Pia Bernasconi;Fulvio Baggi

  • The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates

    Serena Pellegatta;Marica Eoli;Simona Frigerio;Carlo Antozzi

  • COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

    Maria Pia Sormani;Irene Schiavetti;Luca Carmisciano;Cinzia Cordioli

  • Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis

    Fulvio Baggi;Francesca Andreetta;Elisabetta Caspani;Monica Milani

  • Titin antibodies in “seronegative” myasthenia gravis — A new role for an old antigen

    C. Stergiou;K. Lazaridis;V. Zouvelou;J. Tzartos

  • Removal of antiacetylcholine receptor antibodies by protein-A immunoadsorption in myasthenia gravis.

    E. Berta;P. Confalonieri;O. Simoncini;G. Bernardi

  • Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide.

    Serena Pellegatta;Marica Eoli;Valeria Cuccarini;Elena Anghileri

Frequent Co-Authors

Renato Mantegazza
Renato Mantegazza Istituto Neurologico Carlo Besta
Angela Vincent
Angela Vincent University of Oxford
Carolina Frassoni
Carolina Frassoni Istituto Neurologico Carlo Besta
Silvana Franceschetti
Silvana Franceschetti Istituto Neurologico Carlo Besta
Jorge R. Oksenberg
Jorge R. Oksenberg University of California, San Francisco
Lucia Mori
Lucia Mori University of Basel
Raffaele A. Calogero
Raffaele A. Calogero University of Turin
Lawrence Steinman
Lawrence Steinman Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare degrees offer diverse career opportunities. Nursing professionals, for example, can explore specializations that complement immunological knowledge, such as acute care. Transitioning from a family nurse practitioner (FNP) role to acute care requires additional certification, and understanding the fnp to acute care certification pathway is essential.

Accelerated programs have made it easier for aspiring practitioners to enter the field quickly. The accelerated nurse practitioner program options provide focused education for those ready to advance their clinical skills efficiently.

For individuals without a nursing background looking to enter healthcare, 12-month accelerated nursing programs online for non nurses offer a streamlined path into nursing careers closely tied to immunology-related roles.

Salary considerations also play a key role in career planning. Understanding the dnp salary by specialty can help candidates make informed decisions about their education investments and future job markets in related fields.

Best Scientists Citing Carlo Antozzi

Trending Scientists